Abstract
Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).
Publication types
-
Case Reports
-
Clinical Trial, Phase I
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Abdominal Neoplasms / drug therapy*
-
Abdominal Neoplasms / genetics
-
Adult
-
Anaplastic Lymphoma Kinase
-
Crizotinib
-
Granuloma, Plasma Cell / drug therapy*
-
Granuloma, Plasma Cell / genetics
-
Humans
-
Male
-
Mutation
-
Neoplasms, Muscle Tissue / drug therapy*
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Protein-Tyrosine Kinases / genetics*
-
Proto-Oncogene Proteins c-met / antagonists & inhibitors
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use*
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Receptor Protein-Tyrosine Kinases
-
Receptors, Growth Factor / antagonists & inhibitors
-
Young Adult
Substances
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyridines
-
Receptors, Growth Factor
-
Crizotinib
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
MET protein, human
-
Protein-Tyrosine Kinases
-
Proto-Oncogene Proteins c-met
-
Receptor Protein-Tyrosine Kinases
Associated data
-
ClinicalTrials.gov/NCT00585195